CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based company that is committed to iPSC-derived innate immune cell therapeutics, announced on Monday that it has entered into a global strategic collaboration agreement with Qilu Pharma, a vertically integrated pharmaceutical company in China.
Under the collaboration agreement, Qilu Pharma is to develop, manufacture and commercialise proprietary 'off-the-shelf' induced pluripotent stem cell- (iPSC) derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) intended for cancer immunotherapy. Both parties will take advantage of technologies and expertise and merge capabilities of R&D, manufacturing and marketing to produce CAR-iMAC clinical products intended for solid tumours.
Dr Jin Zhang, CellOrigin Biotech co-founder and a principal investigator of Zhejiang University, said, 'Innovation and offering the best products that benefit patients are the core values that CellOrigin Biotech and Qilu Pharma both appreciate. This is what brings us together.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886